Table 1 Session characteristics, maximum symptom relief, and side effects when using inhaled, dried Cannabis flower
% or mean | N or Std. Dev. | Minimum | Maximum | |
|---|---|---|---|---|
Panel A: THC (2306 symptom-sessions, 670 users) | ||||
%/dry wt. THC | 17.27 | (7.51) | 0 | 30 |
THC < 10% | 21% | 476 | 0 | 1 |
THC 10–19% | 39% | 907 | 0 | 1 |
THC 20–30% | 40% | 923 | 0 | 1 |
Panel B: CBD (2306 symptom-sessions, 670 users) | ||||
%/dry wt. CBD | 6.27 | (6.30) | 0 | 29 |
CBD < 1% | 23% | 528 | 0 | 1 |
CBD 1–9% | 45% | 1049 | 0 | 1 |
CBD 10–30% | 32% | 729 | 0 | 1 |
Panel C: subspecies (2306 symptom-sessions, 670 users) | ||||
Hybrid | 53% | 1230 | 0 | 1 |
C. indica | 27% | 617 | 0 | 1 |
C. sativa | 20% | 459 | 0 | 1 |
Panel D: inhalation method (2306 symptom-sessions, 670 users) | ||||
Joint | 17% | 390 | 0 | 1 |
Pipe | 40% | 927 | 0 | 1 |
Vape | 43% | 989 | 0 | 1 |
Panel E: outcome and control variables (2306 symptom-sessions, 670 users) | ||||
Baseline symptom intensity | 5.45 | (2.14) | − 10 | 0 |
Minimum symptom intensity | 1.63 | (1.80) | 1 | 10 |
Symptom change | − 3.82 | (2.16) | 0 | 10 |
Panel F: side effects (1519 sessions, 559 users) | ||||
Any negative side effect | 63% | 954.00 | 0 | 1 |
% of negative side effects | 10% | (0.12) | 0 | 0.82 |
Any positive side effect | 97% | 1471.00 | 0 | 1 |
% of positive side effects | 28% | (0.18) | 0 | 1 |
Any context-specific side effect | 81% | 1234.00 | 0 | 1 |
% of context-specific side effects | 19% | (0.16) | 0 | 0.91 |